Product Code: GVR-4-68040-064-6
Endomyocardial Biopsy Market Growth & Trends:
The global endomyocardial biopsy market is anticipated to reach USD 543.0 million by 2030 and is anticipated to expand at a CAGR of 6.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as increasing prevalence of Cardiovascular Disorders (CVDs), rising demand for minimally invasive surgical procedures, and favorable reimbursement policies for coronary intervention procedures.
An increase in technological advancements and investment of multinational companies in emerging economies serve as ideal opportunities for the growth and expansion of a market. There is a trend of healthcare reforms and advancements in technology for medical products and devices in emerging economies. This creates an opportunity for manufacturers to introduce their products and capture a significant portion of the market. Countries like India, China, and others are developing and are bringing about incremental changes to their healthcare systems, providing enhanced treatment options to patients.
Furthermore, the well-established healthcare infrastructure in developed countries enables easy accessibility to advanced diagnostic and treatment options. According to data published by the United Network for Organ Sharing, in 2022, over 4,111 heart transplants were performed in the U.S. As the number of heart transplants increases, the need for regular monitoring and early detection of rejection would also increase. This would further boost the demand for endomyocardial biopsy procedures.
Endomyocardial Biopsy Market Report Highlights:
- The forceps segment dominated the product segment with the largest revenue share of 71.9% in 2024, primarily driven by the growing prevalence of cardiovascular diseases and advancements in medical technology.
- Accessories are expected to grow at a lucrative CAGR of 6.3% growth over the forecast period, owing to the rising number of cardiac procedures and the need for specialized tools.
- The straight tip segment dominated the global endomyocardial biopsy market and held the largest revenue share of 36.2% in 2024, attributed to their precision, ease of use, and suitability for routine procedures as well as their straightforward design, which allows for efficient tissue collection, reducing procedure time and enhancing sample reliability.
- Pre-curved tips are expected to grow at a significant CAGR over the forecast period, driven by their enhanced maneuverability and capability to navigate complex cardiac anatomy.
- Hospital held the largest revenue share in 2024. The ambulatory surgery center (ASC) segment is anticipated to grow at a CAGR of 6.0% over the forecast period.
- North America dominated the global endomyocardial biopsy market with the largest revenue share in 2024, driven by advanced healthcare infrastructure, increasing prevalence of cardiovascular diseases, rising heart transplant procedures, and growing awareness of early disease diagnosis.
- Asia Pacific market is projected to grow at the fastest CAGR from 2025 to 2030, attributed to a rising geriatric population, increasing occurrence of cardiac disorders, improving healthcare access, and government initiatives.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Tip
- 1.2.3. End Use
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.8. List of Secondary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product Outlook
- 2.2.2. Tip Outlook
- 2.2.3. End Use Outlook
- 2.2.4. Regional Outlook
- 2.3. Competitive Insights
Chapter 3. Global Endomyocardial Biopsy Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Global Endomyocardial Biopsy Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.2.1. Political Landscape
- 3.3.2.2. Technological Landscape
- 3.3.2.3. Economic Landscape
Chapter 4. Global Endomyocardial Biopsy Market: Product Business Analysis
- 4.1. Product Segment Dashboard
- 4.2. Endomyocardial Biopsy Market: Product Movement Analysis
- 4.3. Global Endomyocardial Biopsy Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
- 4.4. Forceps
- 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 4.5. Accessories
- 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Global Endomyocardial Biopsy Market: Tip Business Analysis
- 5.1. Tip Segment Dashboard
- 5.2. Endomyocardial Biopsy Market: Tip Movement Analysis
- 5.3. Global Endomyocardial Biopsy Market Size & Trend Analysis, By Tip, 2018 to 2030 (USD Million)
- 5.4. Maxi-curved
- 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 5.5. Straight
- 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 5.6. Pre-curved
- 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 5.7. Others
- 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. Global Endomyocardial Biopsy Market: End Use Business Analysis
- 6.1. End Use Segment Dashboard
- 6.2. Endomyocardial Biopsy Market: End Use Movement Analysis
- 6.3. Global Endomyocardial Biopsy Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
- 6.4. Hospitals
- 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 6.5. Ambulatory Surgical Centers
- 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 6.6. Others
- 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Global Endomyocardial Biopsy Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Dashboard
- 7.2. Regional Market Share Analysis, 2024 & 2030
- 7.3. Global Endomyocardial Biopsy Market by Regional: Key Takeaways
- 7.4. North America
- 7.4.1. U.S.
- 7.4.1.1. Key Country Dynamics
- 7.4.1.2. Regulatory Framework/ Reimbursement Structure
- 7.4.1.3. Competitive Scenario
- 7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.4.2. Canada
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Regulatory Framework/ Reimbursement Structure
- 7.4.2.3. Competitive Scenario
- 7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.4.3. Mexico
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Regulatory Framework/ Reimbursement Structure
- 7.4.3.3. Competitive Scenario
- 7.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Germany
- 7.5.1.1. Key Country Dynamics
- 7.5.1.2. Regulatory Framework/ Reimbursement Structure
- 7.5.1.3. Competitive Scenario
- 7.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Regulatory Framework/ Reimbursement Structure
- 7.5.2.3. Competitive Scenario
- 7.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.3. France
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Regulatory Framework/ Reimbursement Structure
- 7.5.3.3. Competitive Scenario
- 7.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.4. Italy
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Regulatory Framework/ Reimbursement Structure
- 7.5.4.3. Competitive Scenario
- 7.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.5. Spain
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Regulatory Framework/ Reimbursement Structure
- 7.5.5.3. Competitive Scenario
- 7.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.6. Denmark
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Regulatory Framework/ Reimbursement Structure
- 7.5.6.3. Competitive Scenario
- 7.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Regulatory Framework/ Reimbursement Structure
- 7.5.7.3. Competitive Scenario
- 7.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.8. Norway
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Regulatory Framework/ Reimbursement Structure
- 7.5.8.3. Competitive Scenario
- 7.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.1.1. Key Country Dynamics
- 7.6.1.2. Regulatory Framework/ Reimbursement Structure
- 7.6.1.3. Competitive Scenario
- 7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.2. China
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Regulatory Framework/ Reimbursement Structure
- 7.6.2.3. Competitive Scenario
- 7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.3. India
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Regulatory Framework/ Reimbursement Structure
- 7.6.3.3. Competitive Scenario
- 7.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.4. Australia
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Regulatory Framework/ Reimbursement Structure
- 7.6.4.3. Competitive Scenario
- 7.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.5. Thailand
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Regulatory Framework/ Reimbursement Structure
- 7.6.5.3. Competitive Scenario
- 7.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Regulatory Framework/ Reimbursement Structure
- 7.6.6.3. Competitive Scenario
- 7.6.6.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Brazil
- 7.7.1.1. Key Country Dynamics
- 7.7.1.2. Regulatory Framework/ Reimbursement Structure
- 7.7.1.3. Competitive Scenario
- 7.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.7.2. Argentina
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Regulatory Framework/ Reimbursement Structure
- 7.7.2.3. Competitive Scenario
- 7.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8. Middle East & Africa
- 7.8.1. South Africa
- 7.8.1.1. Key Country Dynamics
- 7.8.1.2. Regulatory Framework/ Reimbursement Structure
- 7.8.1.3. Competitive Scenario
- 7.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.2. Saudi Arabia
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Regulatory Framework/ Reimbursement Structure
- 7.8.2.3. Competitive Scenario
- 7.8.2.4. South Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.3. UAE
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Regulatory Framework/ Reimbursement Structure
- 7.8.3.3. Competitive Scenario
- 7.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.8.4. Kuwait
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Regulatory Framework/ Reimbursement Structure
- 7.8.4.3. Competitive Scenario
- 7.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. Key Company Heat Map Analysis, 2024
- 8.4. Company Profiles
- 8.4.1. Argon Medica Devices, Inc.
- 8.4.1.1. Company Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Cordis
- 8.4.2.1. Company Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Mermaid Medical
- 8.4.3.1. Company Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Terumo Corporation
- 8.4.4.1. Company Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. Scholten Surgical Instruments, Inc.
- 8.4.5.1. Company Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. Changzhou Lookmed Medical Instrument Co., Ltd.
- 8.4.6.1. Company Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Fehling Instruments
- 8.4.7.1. Company Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives